Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00542230 · ClinicalTrials.gov registry record

Blood Sampling for Research Related to Sickle Cell Disease

A clinical trial of Sickle Cell Disease and Sickle Cell Anemia, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Recruiting
Registry status
250
Enrollment target
1
Study location

NCT00542230: Recruiting study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

NCT00542230 is a study of Sickle Cell Disease and Sickle Cell Anemia that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 250 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00542230, a study of Sickle Cell Disease and Sickle Cell Anemia, is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

RECRUITING
Registry status
250 participants
Enrollment target
1
Study location

Study Summary

This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throughout the body. The purpose of the study is to collect a variety of blood samples that may then be used to investigate advances and potential new drug treatments for sickle cell disease. Volunteers must be at least 18 years of old. Samples will be taken both from healthy volunteers and from volunteers who have unique red blood cell features that are related to sickle cell disease. Candidates will be screened with a medical history. During the study, participants will undergo a one- to two-hour outpatient procedure at the National Institutes of Health Clinical Center. Once researchers have explained the study and obtained the participant s consent, participants will donate 8 cc (approximately 2 teaspoons) of blood. Because repeat testing helps researchers validate study findings, participants who have the unique red blood cell features mentioned above may also be asked if they are willing to return and donate another 2 cc to 8 cc of blood for additional studies. The amount of blood drawn will not exceed 50 ml with any eight-week period for adults or 7 cc within any six-week period for children.

Primary Outcome

To identify by high sensitivity in vitro screening methods additional compounds that inhibit sickling

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2007-11-07

What NCT00542230 shows while recruiting

NCT00542230 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (14% lower).

The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.

NCT00542230 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00542230 about?

NCT00542230 is a clinical study titled "Blood Sampling for Research Related to Sickle Cell Disease". This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throug...

What is the current status of trial NCT00542230?

This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2007-11-07.

What conditions does trial NCT00542230 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Trait.

Who is sponsoring clinical trial NCT00542230?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00542230 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00542230's enrollment target sits among peer trials

250 27th of 213 higher than 186 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00542230, the US trial registry maintained by the National Library of Medicine. NCT00542230 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.